The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...
This meeting comes after a favorable Phase 2, multicenter, non-randomized study of [18F]FAPI-74 in patients with gastrointestinal cancers, which was comprised of patients with gastroesophageal cancers ...
DULLES, Va., Dec. 29, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of ...
Figure 1. Clinical stage changed by FAPI PET/CT categorized by 18 F-FDG PET/CT in newly diagnosed breast cancer. Toronto, Ontario—A comparative analysis between FAPI and 18 F-FDG PET/CT for the ...
FAPI PET/CT may be the better imaging tool to predict renal response to lupus nephritis induction therapy. For noninvasively predicting renal response to lupus nephritis induction therapy, the ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based company, to develop, ...
Predictive value of baseline 68Ga-FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Figure 1. Male, 46 years old, with IIP for 1 month, manifests FDG and FAPI imaging positive. (A, E, the MIP of FDG and FAPI imaging; B-C, axial FDG PET/CT, CT, and the FAPI PET/CT; The SUVmax of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback